PDE11

PDE11A (phosphodiesterase 11A) is a dual-specificity cyclic nucleotide phosphodiesterase that hydrolyzes both cAMP and cGMP, thereby regulating second-messenger signaling and controlling the amplitude of downstream PKA- and cGMP-dependent pathways^[1][2]. PDE11A participates in cellular signaling networks that govern endocrine function, metabolism, and tissue-specific physiological responses through modulation of intracellular cyclic nucleotide turnover^[1][3]. Mechanistically, PDE11A contributes to the regulation of cAMP/cGMP signaling cascades, which influence transcriptional programs and cellular homeostasis across multiple organs^[3][4]. In disease contexts, genetic defects and loss-of-function variants in PDE11A have been associated with adrenocortical disorders, including primary pigmented nodular adrenocortical disease, isolated micronodular adrenocortical disease, adrenocortical hyperplasia, and Cushing syndrome-related phenotypes, supporting a role for disrupted cyclic nucleotide signaling in adrenal tumorigenesis^[1][3][5]. Experimental and pathological studies further demonstrate broad tissue expression of PDE11A, with particularly high expression reported in the prostate and detectable expression in adrenal, testicular, renal, hepatic, pancreatic, pituitary, and skeletal muscle tissues^[3][5]. Compared with related phosphodiesterase isoforms, PDE11A displays distinct biochemical properties, limited sequence similarity to other PDE families, and four splice variants with tissue-specific expression patterns, highlighting unique regulatory functions that cannot be directly inferred from other dual-substrate PDEs^[2][3][6]. For experimental applications, PDE11A-selective inhibitors such as BC11-38 have been developed as research tools to investigate PDE11A-dependent signaling and evaluate its potential as a therapeutic target in endocrine and neurobiological disease models^[6][8].